8月2日，在日医药卫生及相关领域的各路精英齐聚一堂，参加了《仁心会创立半年・我们的梦想与荣耀特别活动》。主办方邀请到了日本中华总商会会长，EPS控股株式会社代表取缔役会长严浩先生作报告。

会议首先由东京大学医学部附属病院特任讲师、仁心会副理事长飯塚陽子博士致欢迎词。飯塚博士长期专注于糖尿病的诊疗工作，并致力于将日本先进的糖尿病治疗理念介绍到中国，2014年因在糖尿病治疗方面对中日交流的贡献而荣获中曽根康弘賞奨励奖。飯塚博士已在中国举行过多次义诊活动，受到了NHK电视台的持续关注。之后理事长刘超博士对仁心会的缘起、特点和梦想等作了生动的展示。

随后严浩先生关于《从留学到创业，从企业管理到商会运作》作了主题演讲。严浩先生和他创立的EPS公司是全球公认日本CRO的奠基者和开拓者。2001年7月，公司在日本创业板成功上市，成为日本第一家上市的CRO企业。2004年，公司由创业板转至东证二部上市，2006年再次升至东证一部上市。如今，EPS已是一个拥有4000多名员工的企业集团，集团旗下拥有30多家子公司，遍布日本、韩国、新加坡、菲律宾、美国、中国大陆、中国台湾、中国香港等，业务范围也涉及新药研发、临床试验开发管理、临床数据统计分析、人才派遣、以及ＩＴ软件开发等高科技领域。

在富士电视台崔隽女士的主持下，严浩先生与现场观众就创业、中日企业文化以及企业管理等问题进行了热烈的互动，最后严浩先生对仁心会的发展提出了中肯的建议，并希望仁心会作为一个年轻的医药领域非盈利性组织在追逐梦想与荣耀的道路上再接再厉，为促进相关领域的合作方面发挥更大的作用。

 

---

关于仁心会
仁心会(www.jinsin.org)是日本最大且活跃程度最高的新生医药组织，奉行严格的入会标准，目前拥有准会员212人，正会员24人，各类赞助会员8人/团体。使命是：致力于中日两国的医疗、健康和福祉，学术文化和科学技术的振兴；促进在日华人更好地融入日本的医药；构筑中日间值得信赖的第三方非盈利组织。7月8日在东京大学举行了《特定非営利活動法人仁心会設立総会》，拟在八月份向东京政府申请。目前仁心会拥有四项核心项目：

1. 学术研究交流平台：
每月一次在东京大学举行的跨越医药上中下游的专业交流会，受到了热衷医疗卫生行业研究、创业、投资和民众等的热烈追捧。

2. 电子期刊平台：
汇聚了中日优秀的医药界及商界精英，研究中日医疗热点学术问题，发掘潜在商业机会。利用团队及会员深厚的学术背景从而创造价值、传播价值、共享价值，促进中日产、学、研，两国六方合作互动。

3. 创造更具包容性的在日医药界华人团体
帮助在日医药界华人更好融入日本社会，共同创造包容、公平、互信社会关系。

4. 国际诊疗合作
将日本先进的医学理念、技术和政策等带到中国，在中国进行义诊或对医师等的培训，以及让中国的医师在日本的医疗单位接受中短期的学习体验，切实地提高中日两国间的医药交流。
医者仁心，仁者无敌，一如既往关注民生，关注社会福祉，将公益事业进行到底。

Enduring Care for the Health Conscious Public Through Empathy and Benevolence

The doctor who has a benevolent heart will be fearless in forging way forward

 

The Semi-Annual Anniversary of Renxin Association

Special Event: Our Dream and Glory

 

On August 2^nd, more than 60 specialists and business leaders reputed in the pharmaceutical and healthcare industries in Japan have gathered in Tokyo and participated in the semi-annual anniversary entitled Our Dream and Glory. We were much privileged to have Mr. Yan Hao, Chairman of Chinese Chamber of Commerce in Japan (CCCJ), and Chairman and CEO of EPS Holdings, Inc., as a keynote speaker.

 

The opening remark was given by Dr. Iizuka Yoko, assistant lecturer in the Faculty of Medicine affiliated Hospital at the University of Tokyo, and vice chairperson of Renxin Association. Dr. Iizuka, a diabetes specialist and clinical practitioner, has for many years been dedicated herself in introducing Japan’s advanced diagnosis, therapeutic methods and technologies to China. She received the Nakasone Yasuhiro Award in 2014 for appreciation of her contribution and efforts in Sino-Japan exchanges regarding diabetes therapeutics. Dr. Iizuka has initiated and participated in several volunteer health diagnoses in local communities in Mainland China and interviewed by the NHK. Dr. Liu Chao, chairperson of Renxin Association has also given a passionate speech on the genesis of Renxin and its organizational functions as well as future dedications.

 

Later, Mr. Yan has made a keynote speech, sharing personal experiences of his early oversea studying days in Japan, becoming an entrepreneur, running his company and leading the CCCJ. EPS Inc., founded and operated under his leadership, has been widely recognized, even in the overseas healthcare industry, as a forerunner of CRO (Clinical Research Organization) in Japan. On July 2001, EPS listed on JASDAQ and became the first CRO company to be listed in Japan. In 2004, it succeeded in forging its way into the Second Section of the Tokyo Stock Exchange while in 2006 further entered the First Section of the same institution, ranking among the most reputed companies in Japan. Today, EPS as a holding company has about 4,000 employees, more than 30 subsidiaries and offices located in Japan, South Korea, Singapore, the Philippines, the USA, mainland China, Taiwan and Hong Kong. The company’s major businesses include new drug development, design and management of clinical experiments, statistical analysis of clinical data, talent dispatch, development of IT software, among others.

 

Interviewed and coordinated by Ms. Cui Jun from Fuji Television, Mr. Yan engaged in active interaction with audience about entrepreneurship, different corporate cultures between China and Japan, issues about business administration and others. He concluded by offering many practical advices to the Renxin Association and encouraged all other founding members to work hard and never give up in pursuit of dreams and glories as a young pharmaceutical and healthcare-oriented NPO like Renxin, which will play a larger role in promoting cooperation within the industry of different fields in the future.

 

About Renxin Association

Renxin Association (www.jinsin.org) is one of the largest and most active non-profit organizations with a special focus in pharmaceutical and other healthcare-related industries in Japan. We adopt a strict membership system and currently have 212 associate members, 24 members and 8 sponsoring individual or corporate members. We dedicate ourselves to: promoting medical, healthcare and welfare conditions between China and Japan, as well as academic diversity regarding science and technology in related fields; facilitating expatriates to better fit in the local pharmaceutical and other healthcare-related industries in Japan; building up credibility and enduring reputation as a third-party NPO among individuals and corporates in Japan and China. On July 8^th 2015, the inaugurating meeting of Renxin Association as a non-profit organization was officially held at the University of Tokyo, and the final application documents to the Tokyo municipal government will be submitted in August this year. Currently Renxin has four core projects:

 

1. Platform of exchanges of academic research and business opportunities

We hold monthly seminars for exchange of new ideas in academia and business. We create an excellent platform and environment to members and interested non-members to discuss their new research findings, entrepreneurial initiatives and investment opportunities in the field, covering the up-, mid- and down-stream of the whole value chain in the healthcare industry.

 

2. Platform of academic publish

Our members and associate members are comprised of medical specialists and practitioners, business executives, academic researchers in the healthcare community between Japan and China. We would like to leverage on this pool of talents to create, disseminate and share values, to sparkle new ideas in the academic field through discussion of latest research findings, and to look for business opportunities. We encourage member researchers to have more active participation in publishing the findings of their research and promote academic diversity within the Renxin Association.

 

3. Platform for exchanges among expatriate Chinese in Japan in the healthcare-related industries

We hope to help expatriate Chinese specialists and businesspersons in the pharmaceutical and healthcare industries to better adapt themselves in Japan’s social environment, and to facilitate them in expanding their network based on inclusiveness, fairness and mutual trust.

 

4. Platform of international cooperation in disease diagnosis and therapy

We hope to introduce Japan’s advanced practices of clinical diagnosis and treatment, as well as leading technologies in the healthcare industry to China. Through our initiatives such as performing volunteer health diagnoses in local communities in China, organizing short-term training programs for Chinese clinical doctors to improve their skills in Japan’s medical institutions, and among others, we endeavor to act as bridge to further promote cooperation and exchanges in the healthcare industries between the two countries.

 

Our mission is to provide “enduring care for the health conscious public through empathy and benevolence” and we would continue to focus on efforts to enhance the overall level of health status as well as social welfare of the general public. We would stick to our non-for-profit principle throughout our pursuit of excellence.